A role for choline during early stages of mammalian embryogenesis has not been established, although recent studies show that inhibitors of choline uptake and metabolism, 2-dimethylaminoethanol (DMAE), and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH 3 ), produce neural tube defects in mouse embryos grown in vitro. To determine potential mechanisms responsible for these abnormalities, choline metabolism in the presence or absence of these inhibitors was evaluated in cultured, neurulating mouse embryos by using chromatographic techniques. Results showed that 90%-95% of 14 C-choline was incorporated into phosphocholine and phosphatidylcholine (PtdCho), which was metabolized to sphingomyelin. Choline was oxidized to betaine, and betaine homocysteine methyltransferase was expressed. Acetylcholine was synthesized in yolk sacs, but 70 kDa choline acetyltransferase was undetectable by immunoblot. DMAE reduced embryonic choline uptake and inhibited phosphocholine, PtdCho, phosphatidylethanolamine (PtdEtn), and sphingomyelin synthesis. ET-18-OCH 3 also inhibited PtdCho synthesis. In embryos and yolk sacs incubated with 3 Hethanolamine, 95% of recovered label was PtdEtn, but PtdEtn was not converted to PtdCho, which suggested that phosphatidylethanolamine methyltransferase (PeMT) activity was absent. In ET-18-OCH 3 treated yolk sacs, PtdEtn was increased, but PtdCho was still not generated through PeMT. Results suggest that endogenous PtdCho synthesis is important during neurulation and that perturbed choline metabolism contributes to neural tube defects produced by DMAE and ET-18-OCH 3 .
I n adult tissues, choline is an essential nutrient and its metabolites are important for methylation, acetylcholine and phospholipid biosynthesis, and cell signaling (1, 2) . However, how choline and its metabolites are used during gastrulation and neurulation stages of mammalian embryogenesis has not been determined. In a rapidly growing organism, such as an embryo, it is expected that phosphatidylcholine (PtdCho) and sphingomyelin synthesis through the CDP-Choline pathway ( Fig. 1) would be required for cell membrane assembly and that these molecules may also have regulatory roles when hydrolyzed into signaling molecules, such as diacylglycerol and ceramide. Additional PtdCho may also be synthesized through phosphatidylethanolamine-N-methyltransferase (PeMT) (Fig. 1 ). Acetylcholine could function as a growth factor or morphogen during gastrulation, as has been indicated in chick and sea urchin embryos (3) (4) (5) (6) (7) (8) . Finally, the choline and folic acid metabolic pathways are linked through betaine (Fig. 1) . Folic acid is important in the prevention of neural tube defects, possibly by maintaining the balance of homocysteine and methionine (9) (10) (11) (12) (13) . Therefore, as suggested by Klein (12) , choline may also be important in preventing neural tube defects by contributing methyl groups through betaine and lowering homocysteine concentrations.
Previously, we demonstrated that exposure of neurulating mouse embryos in culture to an inhibitor of choline uptake, 2-dimethylaminoethanol (DMAE), or an inhibitor of PtdCho synthesis, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH 3 ), caused growth and developmental abnormalities (14) , which suggests that choline and its metabolites are important for normal embryogenesis. Therefore, to delineate how gastrulation/neurulation stage embryos use choline and to determine biochemical mechanisms associated with the developmentally toxic effects of DMAE and ET-18-OCH 3 , control and inhibitor-treated mouse embryos were incubated in vitro with radiolabeled choline or ethanolamine. High-pressure liquid and thin-layer chromatography were used to evaluate choline uptake and the metabolism of choline or ethanolamine by the embryo and visceral yolk sac. Reverse transcription (RT) polymerase chain reaction and immunoblotting were used to analyze mRNA expression of betaine homocysteine methyltransferase and presence of choline acetyltransferase, respectively. Inhibitor effects on diacylglycerol and ceramide were also studied.
MATERIALS AND METHODS
Whole embryo culture and sample collection for chromatography ICR mice (Harlan Laboratories, Indianapolis, IN) were mated overnight. Mating was confirmed by the presence of a sperm plug, which was designated gestational day (GD) 1. On GD 9, embryos were prepared for culture as described previously (15) . The uterine decidua, parietal yolk sac, and Reichert's membrane were removed; 4-5 somite stage embryos, with the visceral yolk sac, ectoplacental cone, and amniotic membrane intact, were incubated in immediately centrifuged rat serum (16) and tyrodes buffer (Sigma, St. Louis, MO) (3:1) at 37°C, rotating at 30 rpm. Before inhibitors were added to the culture medium, 2-dimethylaminoethanol (Sigma) was mixed with tyrodes and ET-18-OCH 3 (Kamiya Biomedical Co., Seattle, WA) was sonicated in rat serum for 10 min at 37°C.
All embryos were gassed with 5% O 2 , 5% CO 2 , and 90% N 2 at the start of culture, and, in 24-h studies, after 10 h. At 7 or 21 h of culture, 3.0 µCi /ml of methyl 14 C-choline chloride (200 µCi/ml, 50-62 mCi/mmol; Amersham Pharmacia Biotech, Piscataway, NJ) or 3 H-ethanolamine hydrochloride (1 mCi/ml, 15-40 Ci/mmol; Amersham) was added, and cultures were gassed with 5% O 2 , 5% CO 2 , and 90% N 2 (at 7 h) or 20% O 2 , 5% CO 2 , and 75% N 2 (at 21 h) and incubated for another 3 h. Embryos were then terminated in cold tyrodes buffer, the visceral yolk sac was removed, and both embryos and yolk sacs were rinsed three times in cold tyrodes and stored separately on ice until 6 (24-h culture) or 12 (10-h culture) of each were pooled. Samples were then frozen in liquid nitrogen and stored at -80°C. In the samples in which acetylcholine synthesis was analyzed, the tissue was suspended immediately in 1N formic acid and tissue extraction was begun.
High-pressure liquid and thin layer chromatography

Tissue extraction
To separate aqueous and organic choline metabolites, we extracted collected tissue by using a modified version of a method established by Bligh and Dyer (17) , as described by Pomfret et al (18) . We added 125 µl cold distilled water (dH 2 0) or, for acetylcholine analysis, cold 1N formic acid, to each sample of pooled embryos or visceral yolk sacs. Tissues were then sonicated in ice water, and 25 µl was removed and stored at -80°C for protein assay. We added 400 µl of cold methanol (MeOH): chloroform (CHCl 3 ) (2:1) to the remaining 100 µl sample. Samples were placed on ice for 1 h. They were vortexed every 15 min and stored overnight at -20°C. Samples were then vortexed and centrifuged at 4°C, 6,000 rpm, for 5 min. The supernatant was transferred to a fresh tube, the pellet was re-extracted with 250 µl MeOH:CHCl 3 :dH 2 O (2:1:0.8), and supernatants were combined. We then added 100 µl CHCl 3 and 100 µl dH 2 0 added to the supernatant, and samples were vortexed and centrifuged at room temperature (6,000 rpm) for 2 min to separate the aqueous and organic phases. The aqueous phase was then transferred to a fresh tube, and both phases were dried in a Savant SpeedVac Concentrator (Savant Instruments, Inc., Holbrook, NY).
High-pressure liquid chromatography (HPLC)
HPLC was carried out by using the method established by Pomfret et al (18) . The aqueous phase, containing betaine, choline, acetylcholine, glycerophosphocholine, and phosphocholine, was resuspended in 130 µl MeOH:dH 2 O (12:1), injected into a Pecosphere-3C Si Cartridge (Perkin Elmer, Norwalk, CT), and eluted with a binary, nonlinear gradient of acetonitrile:ethanol:acetic acid:1 mol/L ammonium acetate:dH 2 0:0.1 mol/L sodium phosphate (800:68:2:3:127:10, v/v changing to 400:68:44:88:400:10, v/v). Metabolite peaks were detected by an online radiometric detector (LB506C, Berthold Inc., Nashua, NH).
Thin-layer chromatography (TLC)
The method used for thin-layer chromatography was modified from Pomfret and colleagues (18) . The organic phase, containing PtdCho, phosphatidylethanolamine (PtdEtn), lysophosphatidylethanolamine (LPE), and sphingomyelin, was suspended in 30 µl MeOH:CHCl 3 (2:1) and spotted on a "Baker Analyzed" SI 250 PA silica gel plate (VWR Scientific Products, West Chester, PA). To ensure that all of the organic phase was included, we rinsed the tube with 20 µl MeOH:CHCl 3 (2:1), which was added to the original spot on the plate. PtdCho, PtdEtn, LPE, and sphingomyelin standards (10 mM each) were also included on the plate. After drying, the TLC plate was developed in CHCl 3 :MeOH:40% methylamine (60:20:5) for 40 min. We used diphenylhexatriene (0.03%) in CHCl 3 was used to visualize the lipid products. PtdCho, PtdEtn, LPE, and sphingomyelin bands were marked and scraped into scintillation vials. Distilled water (500 µl) was added, samples were vortexed, and, after 1 h, scintillation fluid was added. After incubating overnight at room temperature, samples were then counted in a Wallace 1410 liquid scintillation counter. Choline concentration in the media at the time-labeled choline was added and, at the end of culture, was measured as described by Pomfret and colleagues (18) . The specific activity of choline was then calculated, and all 14 C-choline data were adjusted accordingly.
Protein assay
To adjust for variability in sample size, we determined total protein for each sample by using a Bio-Rad protein assay kit (Bio-Rad Life Science Research, Hercules, CA). In duplicate, 10 µl of each sonicated sample was combined in a glass test tube with 90 µl dH 2 O and 5 ml of 1:4 diluted Bio-Rad dye reagent. After being vortexed, the tubes were incubated for 15 min at room temperature. Absorbance was measured at 595 nm, and total protein was calculated by using a standard curve created with bovine serum albumin.
Reverse-transcription polymerase chain reaction (RT-PCR)
RT-PCR was used to determine whether betaine homocysteine methyltransferase (BHMT) was expressed in GD 9, 9.5, or GD 10 mouse embryos and visceral yolk sacs. Adult liver and kidney were used as BHMT positive controls, and actin primers were used to verify successful RNA isolation.
RNA isolation and DNase treatment
Adult liver; kidney; or GD 9, 9.5, or 10 mouse embryos and their visceral yolk sacs were isolated in cold tyrodes buffer, collected in TRI-REAGENT (Molecular Research Center, Inc., Cincinnati, OH), and stored at -80°C. In order to obtain a significant quantity of mRNA, we pooled approximately 20 GD 9, 10 GD 9.5, and 6 GD 10 embryos or yolk sacs. The tissue was homogenized in TRI-REAGENT and extracted with chloroform. Total RNA was precipitated from the aqueous phase with isopropanol and then washed with 75% ethanol made with diethyl pyrocarbonate treated water (DEPC H 2 0). The RNA pellet was dried and suspended in 20 µl DEPC H 2 0.
In order to eliminate the possibility of DNA contamination, we treated RNA with RQ1 RNasefree DNase (Promega Corporation, Madison, WI). To each 20 µl RNA sample, 5 units (5 µl) DNase, 3 µl 10× reaction buffer (400 mM Tris-HCl [pH 8.0], 100 mM MgSO 4 , and 10 mM CaCl 2 ), and 2 µl DEPC H 2 0 were added. The reaction mix was incubated at 37°C for 30 min and stopped with RQ1 DNase Stop Solution (20 mM EGTA, pH 8.0), and the DNase was inactivated with a 10-min incubation at 65°C. The RNA was then re-isolated with phenol/chloroform extraction and ethanol precipitation with 3 M sodium acetate. The precipitated pellet was washed with 75% ethanol, dried, and resuspended in 20 µl DEPC H 2 0.
Reverse-transcription, PCR amplification, and agarose gel electrophoresis
We used a GeneAmp RNA PCR kit (Perkin Elmer, Foster City, CA) for mRNA transcription and cDNA amplification. DEPC H 2 O (6 µl), MgCl 2 (25 mM; 4 µl), 10× PCR buffer (500 mM KCl, 100 mM Tris-HCL, pH 8.3; 2 µl), deoxynucleotides (2 µl each), RNase inhibitor (1 µl), MuLV reverse transcriptase (1 µl), and random hexamers (1 µl) were added to 3 µl of the DNase-treated RNA preparation for a total volume of 20 µl. To allow for primer extension, we incubated the mixture for 10 min at room temperature. The reaction was then incubated in a Perkin Elmer DNA Thermal Cycler at 42°C for 1 h, 95°C for 5 min (heat inactivation), and 5°C for 5 min. We split the RT reaction mixture in order to amplify both BHMT and actin cDNA for each sample. For the PCR reaction, primers, additional MgCl 2 and 10× PCR buffer, dH 2 O, and AmpliTaq DNA polymerase were added to 10 µl of the cDNA generated in the RT reaction. The primers used were as follows: The conditions for BHMT cDNA amplification were: cycle 1, 94°C for 5 min, 57°C for 1 min, 72°C for 1 min; cycles 2-34, 94°C for 1 min, 57°C for 1 min, 72°C for 1 min; cycle 35, 94°C for 1 min, 60°C for 10 min. For β-actin cDNA the conditions were cycle 1, 94°C for 5 min, 57°C for 1 min, 72°C for 1 min; cycles 2-24, 94°C for 1 min, 57°C for 1 min, 72°C for 1 min; and cycle 25, 94°C for 1 min, 60°C for 10 min. PCR products and a molecular-weight standard were run on a 3% agarose gel containing 0.5 µg/ml ethidium bromide for 30 min at 105 volts.
Immunoblot
Western blotting was used to determine whether choline acetyltransferase (ChAT) was present in GD 9, 9.5, or 10 mouse embryos and visceral yolk sacs. Adult and fetal (GD 15) brain were selected as positive controls. Samples were collected and homogenized on ice in 0.0625M TrisHCl, pH 6.8, and 2% SDS. We used a Bio-Rad DC protein assay kit (Bio-Rad Life Science Research) to determine protein concentration according to the manufacturer's instructions. Six microliters of a modified version of 5X Laemmli sample buffer (19) (50% glycerol, 25% β-mercaptoethanol, 0.5% bromophenyl blue, 0.0625 M Tris-HCl, 2% SDS) were added to 50 µg of protein, and 0.0625M Tris-HCl -2% SDS was used to bring the volume to 30 µl. Bio-Rad Prestained Precision Protein Standards (Bio-Rad Life Science Research) and protein samples were loaded onto Novex TM (San Diego, CA) 10% polyacrylamide tris-glycine pre-cast mini gels. Two gels were run simultaneously with 1X Novex TM Tris-Glycine running buffer for 2 h at 40 mA. Proteins were transferred to pre-wet (3 min MeOH, 5× dH 2 0 rinse, 5 min Towbin transfer buffer) polyvinylidene difluoride membranes in cold (4°C) Towbin transfer buffer (192 mM glycine, 25 mM Tris base (pH 8.3), 0.5% SDS, 15% methanol) (20) for 1 h at 400 mA. The membranes were blocked for 1 h at room temperature in 5% milk in 1× PBS-0.1% Tween (PBS-T) and then were incubated overnight at 4°C with 1:5,000 goat anti-ChAT antibody (Chemicon International, Temecula, CA) diluted in 1% milk in PBS-T. Membranes were washed six times (10-15 min each) with PBS-T and then were incubated 1 h at room temperature with 1:50,000 peroxidase conjugated rabbit anti-goat IgG (Pierce, Rockford, IL) diluted in 1% milk in PBS-T. After being washed six times (10-15 min each) in PBS-T, membranes were washed twice (15 min each) in PBS and treated with SuperSignal West Dura Extended Duration Substrate (Pierce) for 5 min at room temperature. Excess SuperSignal was removed and blots were exposed to film.
All membrane incubations were done on a shaker at 50 rpm. Gels were stained with Coomassie blue to confirm transfer.
Diacylglycerol and ceramide assay
After 24 h of culture, control and inhibitor treated embryos and their visceral yolk sacs were collected and rinsed in cold tyrodes, pooled (12 embryos or yolk sacs per sample), frozen in liquid nitrogen, and stored at -80°C. Diacylglycerol and ceramide levels were measured according to the method described by Previati and colleagues (21) . Samples were homogenized in 250 µl cold dH 2 O by sonication on ice, and an aliquot (50 µl) was removed for a Lowry protein assay (22) in order to normalize sample size variability. The remaining sample (200 µl) was extracted with 4 ml MeOH:CHCl 3 (1:2) for 30 min. Distilled water (1 ml) was added, and the samples were centrifuged at 1,000 rpm for 5 min. The aqueous phase was transferred to a fresh tube and washed with CHCl 3 (2 ml). After centrifugation, the aqueous phase was removed to a new tube. The organic phases from both extractions were pooled, dried in a Savant SpeedVac Concentrator (Savant Instruments, Inc.), and stored in a small volume of chloroform at -20°C.
The lipid phase was solubilized in 100 µl anhydrous chloroform and 10 µl each of 100 mM NAP ((S)-6-methoxy-methyl-2-naphthaleneacetic acid), 100 mM DCC (N,N'-dicyclohexylcarbodiimide), and 100 mM DMAP (4-dimethylaminopyridine) in anhydrous CHCl 3 was added. Samples were mixed and incubated at -20°C for at least 3 h. Drying in the SpeedVac stopped the reaction. Samples were then resuspended in CHCl 3 (15 µl), extracted with hexane (2 ml), and centrifuged. The supernatant was transferred to a new tube and mixed with 5 ml MeOH:dH 2 0 (4:1). Following centrifugation, the organic (top) phase was removed and the aqueous phase was re-extracted as above. The organic phases were pooled, dried in the SpeedVac, and dissolved in hexane (1 ml), and 50 µl was injected onto an Econosphere CN HPLC column (Alltech, Deerfield, IL). Diacylglycerol and ceramide were eluted with a gradient of hexane and 3% 2-propanol in hexane (90:10 to 0:100 to 98:2 v/v) and detected with a Prostar 360 fluorescent detector (Varian Instruments, Walnut Creek, CA).
Statistical analysis
Repeated measures analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test was used to compare diacylglycerol and ceramide levels in control and inhibitor-treated embryos and yolk sacs after 24 h of culture. Labeled choline and ethanolamine metabolites measured after 10 h embryo culture were compared between control and inhibitor treated embryos or yolk sacs by using ANOVA followed by Dunnett's multiple comparisons test. A metabolite comparison between control and ET-18-OCH 3 treated embryos or yolk sacs cultured 24 h was made by using a two-tailed t-test. A P-value less than or equal to 0.05 was considered significant.
RESULTS
Choline utilization by gastrulation and neurulation stage mouse embryos and abnormal choline metabolism in inhibitor treated embryos and visceral yolk sacs
To evaluate choline metabolism and to determine biochemical mechanisms associated with previously observed teratogenic effects of DMAE and ET-18-OCH 3 , we used HPLC and TLC to measure the uptake and incorporation of 14 C-choline into choline metabolites in control and inhibitor-treated embryos and their visceral yolk sacs (Figs. 2-4 ). In addition, PtdCho synthesis through the PeMT pathway was evaluated by using 3 H-ethanolamine (Figs. 5, 6 ). Embryos were exposed to previously determined teratogenic doses of DMAE (375 µM) or ET-18-OCH 3 (275 µM), which had been shown to cause a greater than 90% malformation rate (14) , for 7 or 21 h before the addition of 14 C-choline or 3 H-ethanolamine. Control cultures received only vehicle for the same incubation period. After a 3-h incubation with the labeled metabolite, cultures were terminated and tissue was collected for HPLC and TLC.
After 10 h of culture, 95% of 14 C-choline detected in control embryos was in the form of phosphocholine (69%) and PtdCho (26%) (Fig. 2) . In control visceral yolk sacs, 78% of labeled choline was in phosphocholine and 14% in PtdCho. In embryos and yolk sacs cultured for 24 h, ~90% of 14 C-choline was detected in phosphocholine and PtdCho (Fig. 4) . The distribution of these metabolites in 24-h visceral yolk sacs was similar to the pattern at 10 h (72% phosphocholine, 17% PtdCho); whereas in the 24-h embryo, 40% of the 14 C-choline was in the form of phosphocholine and 57% PtdCho. At both time points, the remaining 14 C-choline detected was free choline, betaine, glycerophosphocholine (not shown), or sphingomyelin. In a separate experiment in which samples were treated with formic acid in order to prevent acetylcholine degradation, approximately 1% of 14 C-choline could be detected as acetylcholine (ACh) in visceral yolk sacs from both 10-and 24-h cultures, but no labeled ACh was observed in cultured embryos (data not shown). Finally, in both embryos and yolk sacs cultured 10 or 24 h and incubated with 3 H-ethanolamine, approximately 95% of radiolabel detected in the lipid phase was in the form of phosphatidylethanolamine (PtdEtn) and the remainder was found in lysophosphatidylethanolamine (LPE), a PtdEtn metabolite (Figs. 5, 6 ). No 3 H-label was detected in PtdCho.
After 10 h of embryo culture with 375 µM DMAE, the amount of labeled choline in the embryo was reduced by 60% (Fig. 2) . However, choline uptake by the visceral yolk sac appeared to be unaffected. In both yolk sacs and embryos treated with DMAE, the incorporation of labeled choline into phosphocholine, PtdCho, and sphingomyelin was reduced to approximately 25%, 35%, and 50% of control values, respectively. In the DMAE-treated embryos, the amount of labeled choline in betaine was approximately threefold higher than in controls. Treatment with DMAE also caused a reduction in PtdEtn and LPE synthesis from labeled ethanolamine in both embryos and visceral yolk sacs (Fig. 5) .
The effects of 275 µM ET-18-OCH 3 on choline uptake and metabolism were evaluated after both 10 and 24 h of whole embryo culture (Figs. 3, 4) . We had described previously the effects of ET-18-OCH 3 on phosphocholine and PtdCho synthesis after 10 h of embryo culture (14) , and, for continuity, these data are also reported in Figure 3 . In visceral yolk sacs after 10 or 24 h and, in embryos after 24 h, treatment with ET-18-OCH 3 resulted in almost twice the amount of labeled phosphocholine compared with controls. After 10 h of culture, PtdCho and sphingomyelin accumulation was reduced by approximately 50% in embryos exposed to ET-18-OCH 3 . A trend toward reduced PtdCho (P = 0.0675) and reduced sphingomyelin (P ≤ 0.05) accumulation was also observed in 24-h ET-18-OCH 3 treated embryos. Treatment with ET-18-OCH 3 also appeared to produce a pattern of elevated labeled betaine in embryos after 10-and 24-h culture, and a significant increase in betaine was observed in visceral yolk sacs after 24 h. Additionally, free 14 C-choline levels were found to be twice as high as control values in embryos treated with ET-18-OCH 3 for 24 h. In visceral yolk sacs from embryos incubated with 3 H-ethanolamine, ET-18-OCH 3 treatment resulted in a 25%-30% increase in PtdEtn synthesis, but PtdCho synthesis through the PeMT pathway was not observed (Figs. 5, 6 ).
Betaine homocysteine methyltransferase was expressed at later neurulation stages, but 70 kDa choline acetyltransferase was absent from neurulating mouse embryos
We found that betaine could be synthesized from choline and that the activity of this oxidative pathway appeared to be elevated in DMAE and ET-18-OCH 3 inhibitor treated embryos (Figs. 2-4) . To determine whether betaine can contribute to methionine synthesis during these stages of development, RT-PCR was used to determine whether betaine homocysteine methyltransferase was expressed in GD 9, 9.5, and 10 embryos and their visceral yolk sacs (Fig. 7) . Results showed that BHMT was not expressed in either yolk sac or embryonic tissue until GD 10, when neurulation was nearly complete.
The biochemical studies described above also indicated that acetylcholine was synthesized in the visceral yolk sac after 10 and 24 h of embryo culture. Immunoblotting was used to determine whether choline acetyltransferase could be detected in GD 9, 9.5, and 10 embryos and yolk sacs, using adult and fetal (GD 15) brain tissue as controls (Fig. 8) . In adult brain, the anti-ChAT antibody labeled two protein bands of 70 kDa and 45 kDa. However, 70 kDa ChAT was undetectable in fetal brain and absent in GD 9-10 embryos and yolk sacs. In fetal brain and embryos, the antibody instead labeled a 50 kDa protein band. In embryos, yolk sacs, and fetal brain, a 40 kDa anti-ChAT labeled protein band was also observed.
Diacylglycerol and ceramide levels were altered in inhibitor treated embryos
Diacylglycerol (DAG) and ceramide (CER) are important in the synthesis of PtdCho and sphingomyelin ( Fig. 1) and are released when these phospholipids are hydrolyzed (23) . Inhibiting choline uptake and metabolism with DMAE or ET-18-OCH 3 could alter the relative proportion of DAG and CER available to embryonic cells for cell signaling and the synthesis of PtdCho and sphingomyelin. Therefore, HPLC was used to evaluate the effects of these inhibitors on DAG and CER after 24 h of whole embryo culture (Fig. 9) . Compared with controls, diacylglycerol concentrations were elevated by 17% in ET-18-OCH 3 treated embryos, but remained similar to control values in embryos treated with DMAE. In addition, treatment with either DMAE or ET-18-OCH 3 resulted in a 15% and 25% increase, respectively, in embryonic ceramide concentrations. Compared with controls, there was no significant difference in the levels of DAG or CER in the visceral yolk sacs from ET-18-OCH 3 or DMAE treated conceptuses.
DISCUSSION
Choline metabolism by gastrulation and neurulation stage mouse embryos and their visceral yolk sacs was investigated by tracing the metabolism of labeled choline or ethanolamine with HPLC and TLC. Previous studies demonstrated choline kinase and CTP: phosphocholine cytidylyltransferase activity in preimplantation stage mouse embryos (24, 25) . In our experiments, the synthesis of phosphocholine and PtdCho from 14 C-choline in cultured embryos and yolk sacs indicates that these enzymes are also present and active during gastrulation and neurulation stages of development (Figs. 2-4) . In adult tissues, PtdCho is usually the most prominent choline metabolite (18, 26) . Therefore, the high ratio of phosphocholine to PtdCho observed in embryos after 10 h of culture and in visceral yolk sacs after either 10 h or 24 h of culture, suggests that, at these stages of development, the CDP-Choline pathway is still developing and may not be as efficient as in adult tissues in converting phosphocholine to PtdCho. After 24 h of culture, there appears to be an increase in PtdCho synthesis in the embryo, suggesting continued maturation of this pathway. However, it should be noted that it is difficult to distinguish whether radioactive counts in the embryo resulted from labeled metabolite being transported from visceral yolk sac to embryo or whether the embryo itself has the capacity to metabolize choline to PtdCho. The visceral yolk sac has been shown previously to possess metabolic activities at these stages of morphogenesis (27) and therefore it is possible that PtdCho is synthesized at this site and then transported to the embryo. In this respect, an increase in labeled PtdCho in the embryo after 24 h of culture may represent more efficient visceral yolk sac synthesis and transfer.
Additional metabolites generated from 14 C-choline in embryos and visceral yolk sacs included betaine, glycerophosphocholine, and sphingomyelin. In visceral yolk sacs, small quantities of labeled acetylcholine were also observed. These results suggest that choline oxidase, PtdCho: ceramide choline phosphotransferase, and, in yolk sacs, choline acetyltransferase are active during neurulation stages of development (Fig. 1) . Betaine has the potential to play an important role during neurulation as a methyl donor for the production of methionine and as a means of lowering homocysteine concentration. Recent studies show that methionine and folic acid can prevent neural tube defects, such as spina bifida and exencephaly, possibly by altering methyl group metabolism and/or reducing elevated homocysteine (9) (10) (11) (12) (13) (28) (29) (30) . In the present study, however, RT-PCR analysis indicated that betaine homocysteine methyltransferase was not expressed until neural tube closure was nearly complete. Hence, choline would not be an acceptable substitute for folic acid as a methyl donor in the prevention of neural tube defects and betaine synthesis may serve only as a shunt for excess choline during gastrulation and neurulation. This conclusion is consistent with results showing that choline could only partially rescue rat embryos grown in methionine deficient medium (12) . However, as this pathway matures, betaine could become important in maintaining the balance between homocysteine and methionine by providing additional methyl groups to the methylation cycle.
Although a small amount of acetylcholine was synthesized from labeled choline in the visceral yolk sac, immunoblot revealed that the typical 70 kDa choline acetyltransferase was not detectable in fetal brain, embryos, or visceral yolk sacs. Instead the ChAT antibody labeled lower molecular weight bands (40-50 kDa) in these tissues. It has been documented that the ChAT gene generates multiple mRNA splice variants (31) (32) (33) (34) . One such variant gives rise to a 50 kDa protein, pChAT, which appears to be localized to the peripheral nervous system (34) and could account for the 50 kDa band observed in fetal brain and embryos. Whether or not the 40-kDa band represents another as yet unidentified splice variant of ChAT remains to be determined. It is also not clear whether these proposed splice variants of ChAT are active in converting choline to acetylcholine. However, the existence of labeled acetylcholine in the visceral yolk sac is indicative of at least some ChAT activity. It is possible that acetylcholine in the visceral yolk sac could act as a growth factor or morphogen during early mammalian embryogenesis, as has been proposed in other species (3) (4) (5) (6) (7) (8) . Other neurotransmitters, such as serotonin, have also been found to have regulatory roles during gastrulation, neurulation, craniofacial, and heart development (reviewed in ref. 8) .
One question that arose from our studies was whether embryos or their surrounding membranes could generate additional PtdCho through the PeMT pathway in order to overcome a block in the CDP-choline pathway for PtdCho synthesis. Our results showed that, although control embryos could synthesize phosphatidylethanolamine (PtdEtn) from labeled ethanolamine, they did not convert PtdEtn to PtdCho via the PeMT pathway. Furthermore, inhibition of the CDP-choline pathway with ET-18-OCH 3 led to increased levels of PtdEtn, but PtdCho was still not generated through PeMT. Therefore, we concluded that gastrulation and neurulation stage mouse embryos must use the CDP-choline pathway to synthesize PtdCho. Consistent with these results, targeted gene disruption of the PeMT gene, pempt, had no observable effect on embryonic growth and development (35) . In addition, PeMT activity was not detectable in the liver until later stages of fetal development (36, 37) .
Considering the potential importance of choline and its metabolites in embryonic development, we hypothesized that alterations in choline metabolism would cause developmental defects during the early stages of embryogenesis. This hypothesis was substantiated in a previous study (14) in which the application of DMAE or ET-18-OCH 3 to embryo culture resulted in neural tube and craniofacial abnormalities. The present study indicates that reduced PtdCho availability due to decreased choline transport and/or an inhibition of PtdCho synthesis could be responsible for the observed defects. For example, free choline levels were lowered in DMAE-treated embryos, but not in visceral yolk sacs, which suggests that DMAE may have inhibited the transport of choline from yolk sac to embryo (Fig. 2) . However, we also observed reduced 14 Clabeled phosphocholine, PtdCho, and sphingomyelin levels in the visceral yolk sac, which suggests that DMAE could be inhibiting choline kinase in this tissue (Fig. 1) . Inhibiting choline kinase could, in turn, allow free choline levels to be maintained in the yolk sac, even if choline uptake from the media was diminished. DMAE treatment also resulted in reduced incorporation of 14 C-choline into phosphocholine, PtdCho, and sphingomyelin in the embryo. It is not clear whether this effect was the result of reduced choline uptake and/or transfer of choline and its metabolites from the visceral yolk sac, or whether there was direct inhibition of embryonic choline kinase by DMAE. Nevertheless, it is apparent that reduced PtdCho availability caused by an inhibition of choline transport and/or repressed choline kinase by DMAE can be teratogenic.
Our results with DMAE are consistent with previous reports that demonstrate that DMAE is a competitive inhibitor of choline uptake and transport in the kidney and placenta (38, 39) and an inhibitor of choline kinase in the kidney and liver (40). DMAE also caused a reduction in phosphatidylethanolamine synthesis from 3 H-ethanolamine, reflecting that, in addition to being a choline analog, DMAE is related structurally to ethanolamine. It was also interesting that betaine levels were elevated in DMAE-treated embryos, a result that is in contrast to reports in the literature that suggest DMAE is an inhibitor of choline oxidase (39) (40) (41) (42) . Instead, during embryogenesis, it appears that the oxidative pathway provided an alternate route for choline that may have accumulated when choline kinase was inhibited.
ET-18-OCH 3 is an antineoplastic agent that has been shown to inhibit PtdCho synthesis at the level of CTP: phosphocholine cytidylyltransferase in cell culture ( Fig. 1) (43, 44) . The pattern of reduced embryonic PtdCho and increased phosphocholine (the immediate precursor of CDPcholine) in visceral yolk sacs at 10 h and 24 h and in embryos after 24 h culture, indicates that ET-18-OCH 3 inhibited the CDP-choline pathway in the conceptus (Figs. 3, 4) . This result also suggests that, at least at the 10 h timepoint, the primary effect on ET-18-OCH 3 on PtdCho synthesis was on the visceral yolk sac. Elevated phosphocholine in 24-h ET-18-OCH 3 -treated embryos is consistent with increased activity of the CDP-choline pathway observed in control embryos cultured for the same length of time. There also appeared to be a trend toward increased betaine synthesis in ET-18-OCH 3 -treated embryos at both time points and in the yolk sac after 24 h culture. Because we demonstrated that BHMT is first expressed on GD 10, a stage equivalent to after 24 h of whole embryo culture, additional betaine could be used for methylation at later stages of development.
Diacylglycerol and ceramide are second messengers involved in signal transduction pathways that regulate apoptosis (45) (46) (47) (48) (49) . In our experiments, compared with controls, diacylglycerol and ceramide levels were higher in ET-18-OCH 3 -treated embryos. Elevated DAG and CER concomitant with reduced PtdCho and sphingomyelin have previously been associated with apoptosis (49, 50) . In addition, an inhibition of PtdCho synthesis by ET-18-OCH 3 has been associated with apoptosis in cell culture (44, (51) (52) (53) (54) (55) and in developing embryos (14) . ET-18-OCH 3 is also an inhibitor of phosphatidylinositol specific phospholipase C and protein kinase C (56, 57). Therefore, in addition to an inhibition of PtdCho synthesis through the CDP-choline pathway, the effects of ET-18-OCH 3 on embryonic development could also reflect abnormal cell signaling.
To conclude, the majority of choline used by cultured embryos and their visceral yolk sacs is phosphorylated to phosphocholine, which is then used for PtdCho synthesis through CDPcholine. An inhibition of the CDP-Choline pathway and reduced choline availability for PtdCho synthesis resulted in increased cell death and developmental defects (14) , which could be the result of inadequate PtdCho for membrane biosynthesis or aberrant cell signaling through PtdCho metabolites. Hence, it is apparent that an endogenous pathway for PtdCho synthesis is required for normal growth and development.
Pregnancy has been shown to deplete choline pools (26, 58) , and the demand for choline by a developing fetus could put the mother and, subsequently, the conceptus at risk for choline deficiency (26) . Prenatal choline deficiency has been associated with modified spatial and temporal memory, shortened attention spans (59, 60) , and resulted in higher levels of apoptosis, reduced cell proliferation, and altered differentiation in the fetal hippocampal region (61, 62) . In adults, choline deficiency and the ensuing abnormalities in choline metabolism caused liver damage in humans and hepatocarcinomas in rats (63) (64) (65) (66) (67) (68) (69) . The current work establishes a critical role for choline during the early stages of organogenesis, a stage when many birth defects are induced. Because pregnant women may be at risk for choline deficiency, and reduced choline availability has been shown to have a negative impact on embryonic and fetal development as well as adult liver, it has been suggested that an increase in dietary choline intake during pregnancy may be beneficial (26, 70) .
The potential teratogenic effects of dimethylaminoethanol are of special concern, as it is currently sold as a nutrient supplement that claims to enhance acetylcholine-related functions, such as memory and learning (71) (72) (73) (74) . A related molecule found in many commercial products, diethanolamine (DEA), has also been shown to disrupt choline metabolism and has caused tumor formation in mice (75, 76). Thus, compounds that alter choline metabolism in adult (DMAE and DEA) and embryonic (DMAE) tissues are readily accessible to pregnant women and have the potential to be teratogenic in humans. BHMT, betaine homocysteine methyltransferase; CDP-Choline, cytidine diphosphocholine; CER, ceramide; CMP, cytidine monophosphate; CTP, cytidine triphosphate; DAG, 1, 2-diacylglycerol; Methyl-THF, methyltetrahydrofolate; MS, methionine synthase; P*, phosphate; PeMT, phosphatidylethanolamine-N-methyltransferase; PtdCho, phosphatidylcholine; SAM, S-adenosyl methionine; THF, tetrahydrofolate. 14 C-Choline metabolism in control (gray bars) or 275 µM ET-18-OCH 3 (diagonally striped bars) treated embryos and yolk sacs after 24 hours of embryo culture. In control embryos and yolk sacs, labeled choline was incorporated into phosphocholine (PCho), phosphatidylcholine (PtdCho), sphingomyelin (SM), and betaine. Treatment with ET-18-OCH 3 resulted in increased embryonic and yolk sac PCho and reduced embryonic PtdCho and SM, (P=0.0675, P < 0.05, respectively). N = 5-6 (control) or 6 (ET-18-OCH 3 ) per point (6 embryos/yolk sacs per N); ± SEM; *P < 0.05 compared with control group (two-tailed t-test). 
